Compare Citius Pharmaceuticals Inc (CTXR) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Hilton Hotels Corporation Common Stock trades at $325.72 (market cap $72.76B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 5342.1× Citius Pharmaceuticals Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Hilton Hotels Corporation Common Stock for 138 Days on average.
| CTXR | HLT | |
|---|---|---|
Market Cap | $13.62M | $72.76B |
Volume | 132,438 | 1,148,634 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $350.22 |
52-Week Low | $0.48 | $256.96 |
Typical Hold Time | 16 Days | 138 Days |
Enterprise Value | $3.79M | $85.78B |
Dividend Yield | — | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Hilton Worldwide (HLT) trades at $320.5, down 0.65% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $348.11. The company has consistently beaten earnings expectations in recent quarters, with Q3 2026 results expected soon. Revenue has grown steadily from $8.8B in 2022 to $12.04B in 2025, though net income margins have fluctuated. Recent news highlights institutional buying and positive travel trends for 2027.
The outlook for HLT is positive, supported by strong earnings performance, analyst optimism, and growth in travel demand. Key risks include high debt levels, with debt-to-asset ratio rising to 73.88% in 2025, and sensitivity to economic cycles affecting travel spending. The stock offers potential upside to the consensus target, but investors should monitor debt management and macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
